At a Glance
TEBIB (Tissue Engineering & Biomaterials Iranian Bunch) is a multi-facility institute specialized in tissue engineering that includes 14 universities, research facilities and advanced medical education centers and aims to develop and commercialize fundamental and applied knowledge in various areas of tissue engineering and organ reconstruction (especially bone, cartilage and skin tissues).
Porteghal Accelerator is the exclusive commercialization, technology transfer and business development partner of TEBIB.
Research areas in TEBIB are mainly focused on design and fabrication of injectable scaffolds and prefabricated based on both natural biopolymers and synthetic polymeric biomaterials for: nerve, bone, cartilage, skin, membranes and cardiovascular tissue regeneration as well as Nano-Targeting Therapy solutions with focus on cancer. At TEBIB we have done two unique research projects on drug delivery systems, nanotechnology for targeting cancer therapy, bio-adhesives, hemostatic agents, surface modification of biomaterials using plasma and laser irradiation and wound dressing.
At TEBIB we have been conducting two unique research projects on drug delivery systems, nanotechnology for targeting cancer therapy as well as research projects on bio-adhesives, hemostatic agents, and surface modification of biomaterials using plasma and laser irradiation and wound dressing. In addition, we are editing and publishing PubMed indexed and ISI listed journal entitled “Progress in Biomaterials” with collaboration of Springer Nature Publishing Company.
A major part of this project is designed to facilitate and accelerate the progress of the country’s valuable research achievements in the field of tissue engineering towards commercial products that are applicable to the treatment and improvement of the health of community members as well as the development of trade partnerships with international organizations and institutions active in the field of biomaterials and tissue engineering. Entrepreneurship, commercialization, technology transfer, investment and the development of new businesses in biotechnology, tissue engineering, biomaterials, and medical engineering are the main axes of this project.
Loss of tissue or organs due to the destruction of injuries or non-injuries causes major health problems, which greatly affects the patient’s condition and lifespan. Traditional treatments such as surgery suggest that the second region of tissue be used to repair or replace tissues or organs that have been degraded. Tissue engineering refers to methods that are based on the use of scaffolds, cells and biologically active molecules for the production of specific functional tissues. The purpose of tissue engineering is to construct structures that are capable of rehabilitating, maintaining and improving the damaged tissue or the entire organ. Construction of tissue engineering products is generally started by constructing a scaffold, which can consist of a wide range of suitable materials from proteins to plastics. When the scaffolds are built, the cells enter the scaffolds. A combination of growth factors can be used to plant cells. In this method, the indicated cells are the main sources for the formation of newly created tissues. On the other hand, the scaffolds synthesized to create a three-dimensional porous structure place the cells inside themselves to form an extracellular matrix and also control the growth of the cell within the body. These synthesized scaffolds are biodegradable and decompose at the same time as tissue regenerates.
There are currently five key projects defined in the TEBIB project, in fields of three-dimensional bone remodeling, cartilage tissue production, and injectable bone gels, the use of 3D printing technology in bone production, and targeted cancerous tissue targeting with biopolymer carriers.